Strand Therapeutics Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Strand Therapeutics Inc. - overview
Established
2017
Location
Boston, MA, US
Primary Industry
Biotechnology
About
Founded in 2017 and headquartered in Massachusetts, US, Strand Therapeutics Inc. specializes in developing programmable, long-acting mRNA therapeutics, focusing on innovative treatments for cancer and other serious diseases through advanced biotechnology. focuses on creating mRNA-based medicines. In August 2025, Strand Therapeutics Inc.
raised USD 153 million in series B funding led by new investor Kinnevik, with participation from other new investors ICONIQ Capital, Regeneron Ventures, JIC Venture Growth Investments, Alderline Group, LG Technology Ventures, Gradiant Corporation, and Amgen Inc. Returning investors Playground Ventures, FPV Ventures, Eli Lilly & Company, ANRI, Potentum, and other unspecified investors also participated in the round.
Current Investors
Alexandria Venture Investments, ANRI, Playground Global, LLC
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.strandtx.com
Verticals
HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only
Strand Therapeutics Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.